CYP2C8及CYP3A4细胞表达体系的构建及其在小分子激酶药物对紫衫醇代谢途径抑制研究中的应用

doi:10.13560/j.cnki.biotech.bull.1985.2016.07.032

摘要/Abstract

摘要： 构建CYP2C8及其3种突变体细胞表达体系,以紫杉醇为底物研究CYP2C8基因多态性对其酶活性的影响,以及构建CYP2C8和CYP3A4共转染细胞体系研究小分子激酶抑制剂对紫杉醇代谢途径的抑制。根据基因文库分别合成CYP3A4以及CYP2C8及其3种突变体CYP2C8*2（805A>T）、CYP2C8*3（416G>A,1196A>G）、CYP2C8*4（792C>G）的基因编码片段,将其连接到PEGFP-N1表达质粒,测序验证。将CYP2C8野生型及其突变体分别转染HepG2细胞,24 h后加入紫杉醇进行孵育,通过建立好的LC-MS/MS方法对代谢物进行定量分析。同时,也将野生型CYP2C8和CYP3A4质粒按一定的浓度比转入HepG2细胞构建共表达体系。并筛选出合适的质粒浓度比转染细胞,在加入紫杉醇孵育时,同时加入小分子激酶抑制剂,考察小分子激酶抑制剂对紫杉醇代谢途径的抑制作用。结果表明,CYP2C8*4代谢酶对紫杉醇的代谢能力存在明显差异,其中CYP2C8 *2和CYP2C8 *3代谢活性分别是野生型的81%（P<0.05）和87%（P<0.05）,而CYP2C8*4则是野生型的65%（P<0.01）。尼洛替尼完全抑制了紫杉醇的代谢,阿法替尼对紫杉醇的两条代谢途径抑制达30%,而伊马替尼选择性抑制了CYPD3A4的活性。不同基因型CYP2C8对紫杉醇的代谢存在差异,可能是导致临床疗效不同的原因。小分子激酶抑制剂在与紫杉醇联合使用时,对紫杉醇代谢的抑制各不相同。

关键词: 紫杉醇, 代谢酶, 基因多态性, 小分子激酶抑制剂, 药物相互作用

Abstract: The aims of this work are to establish the cell expression system of CYP2C8 and its 3 mutants,to study the effects of gene polymorphisms on its enzymatic activities,and to investigate the effects of small molecular kinase inhibitors on paclitaxel metabolism with the established CYP2C8 and CYP3A4 co-transfected cell lines. The gene fragments of CYP3A4,CYP2C8 and its three mutants（CYP2C8*2（805A>T）,CYP2C8*3（416G>A,1196A>G）,and CYP2C8*4（792C>G））were synthesized based on gene bank. Then those fragments were ligated to expression plasmid PEGFP-N1 for sequencing evaluation. Twenty-four hours after the wild and mutant plasmids were transfected into HepG2 cells,paclitaxel was added and incubation proceeded,and then the metabolites were quantitatively detected by well-constructed LC-MS/MS. Concurrently,the wild CYP2C8 and CYP3A4 plasmids in certain concentration ratios were transfected into HepG2 cells,to establish a co-expression system. Screening the plasmids with proper concentration ratio and transfecting them to the cells,adding small molecule kinase inhibitor while adding paclitaxel for incubation,the inhibition of paclitaxel metabolism by small molecule kinase inhibitors was investigated. The results showed that the metabolic enzyme of different CYP2C8 caused the significant difference of paclitaxel metabolic activity,of which the metabolic activity of CYP2C8*2,CYP2C8*3,CYP2C8*4 remained at about 80%（P < 0.05）,87%（P < 0.05）,and 65%（P < 0.01）,respectively,as compared to the wild type. Nilotinib completely inhibited the metabolism of paclitaxel and axitinib showed a 30% inhibition,while imatinib didn’t have any inhibitory effect. As conclusion,different genotypes of CYP2C8 differentially affect the overall paclitaxel metabolism,which might be the reason that results in the varied treatment effect in clinic. Small molecule kinase inhibitors while combined use with paclitaxel may inhibit the metabolism of paclitaxel to different extents.

Key words: paclitaxel, metabolism enzyme, gene polymorphism, small molecule kinase inhibitors, drug-drug interaction

李远,黄洁琼,李佳俊,汪维鹏,张洪建. CYP2C8及CYP3A4细胞表达体系的构建及其在小分子激酶药物对紫衫醇代谢途径抑制研究中的应用[J]. 生物技术通报, 2016, 32(7): 227-233.

LI Yuan HUANG Jie-qiong LI Jia-jun WANG Wei-peng ZHANG Hong-jian. The Construction of CYP2C8 and CYP3A4,and the Inhibition of Paclitaxel Metabolism by Small Kinase Inhibitor[J]. Biotechnology Bulletin, 2016, 32(7): 227-233.

参考文献

[1] Klose TS, Blaisdell JA, Goldstein JA. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs[J]. Journal of Biochemical & Molecular Toxicology, 1999, 13（6）：289-295.
[2] Nebot N, Crettol S, D’Esposito F, et al. Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes[J]. Br J Pharmacol, 2010, 161（5）：1059-1069.
[3] Daily EB, Aquilante CL. Cytochrome P450 2C8 pharmacogenetics：a review of clinical studies[J]. Pharmacogenomics, 2009, 10（9）：1489-1510.
[4] Gertz M, Tsamandouras N, Säll C, et al. Reduced physiologically-based pharmacokinetic model of repaglinide：impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk[J]. Pharmaceutical Research, 2014, 31（9）：2367-2382.
[5] Khan MS, Barratt DT, Somogyi AA. Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib[J]. Xenobiotica, 2016, 46（3）：278-287.
[6] Yu L, Shi D, Ma L, et al. Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro[J]. Biopharmaceutics & Drug Disposition, 2013, 34（5）：278-287.
[7] Fountzilas G, Kalofonos HP, Dafni U, et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer：a phase III study conducted by the Hellenic Cooperative Oncology Group[J]. Annals of Oncol, 2004, 15（10）：1517-1526.
[8] Ramalingam SS, Mlfrankel M. Carboplatin and Paclitaxel in combi-nation with either vorinostat or placebo for first-line therapy of adva-nced non-small-cell lung cancer[J]. J Clin Oncol, 2010, 28（1）：56-62.
[9] 郭培凤, 郭云利. 紫杉醇应用相关不良反应观察[J]. 医学信息, 2014（2）：643.
[10] Monsarrat B, Mariel E, Cros S, et al. Taxol metabolism. Isolation and identification of three major metabolites of taxol in rat bile[J]. Drug Metabolism & Disposition, 1990, 18（6）：895-901.
[11] Walle T, Kumar GN, McMillan JM, et al. Taxol metabolism in rat hepatocytes[J]. Biochemcal Pharmacology, 1993, 46（9）：1661-1664.
[12] Taniguchi R, Kumai T, Matsumoto N, et al. Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4[J]. Journal of Pharmacological Sciences, 2005, 97（1）：83-90.
[13] Wang Y, Wang M, Qi H, et al. Pathway-dependent inhibition of paclitaxel hydroxylation by kinase inhibitors and assessment of drug-drug interaction potentials[J]. Drug Metabolism & Dispos, 2014, 42（4）：782-795.
[14] Leskelä S, Jara C, Leandro-García LJ, et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity[J]. Pharmacogenomics Journal, 2011, 11（2）：121-129.
[15] Hertz DL, Motsinger-Reif AA, Amy Drobish, et al. CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel[J]. Breast Cancer Research & Treatment, 2012, 134（1）：401-410.
[16] Hertz DL, Roy S, Motsinger-Reif AA, et al. CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel[J]. Ann Oncol , 2013, 24（6）：1472-1478.
[17] Graan AJMD, Laure E, Sprowl JA, et al. CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity[J]. Clin Cancer Res, 2013, 19（12）：3316-3324.
[18] Behrendorff JB, Moore CD, Kim KH, et al. Directed evolution reveals requisite sequence elements in the functional expression of P450 2F1 in Escherichia coli[J]. Chemical Research in Toxicology, 2012, 25（9）：1964-1974.
[19] Imaoka S, Yamada T, Hiroi T, et al. Multiple forms of human P450 expressed in Saccharomyces cerevisiae[J]. Biochemical Pharmacology, 1996, 51（8）：1041-1050.
[20] 路珂, 曾苏, 姚形炜. 利用细菌/杆状病毒系统在昆虫细胞中表达人CYP2E1[J]. 浙江大学学报：医学版, 2008, 37（2）：118-125.
[21] Gerets HHJ, Tilmant K, Gerin B, et al. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins[J]. Cell Biology & Toxicology, 2012, 28（2）：69-87.
[22] 薛正楷. 稳定表达人CYP3A4基因与Bama小型猪CYP3A基因的HepG_2细胞株的建立及探针药物代谢表征的比较研究[D]. 重庆：重庆医科大学, 2009.
[23] Westerink WMA, Schoonen WGEJ. Cytochrome P450 enzyme levels in Hepg2 cells and cryopreserved primary human hepatocytes and their induction in Hepg2 cells[J]. Toxicology in Vitro, 2007, 21（8）：1581-1591.
[24] 谢章明, 陈枢青. 人CYP的异源表达及其在新药研发早期的作用[J]. 浙江大学学报：医学版, 2013, 1（1）：109-113.
[25] Vignati L, Turlizzi E, Monaci S, et al. An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics[J]. Toxicology, 2005, 216：154-167.
[26] 梁艳, 李彦, 白清清. CYP450基因多态性研究进展[J]. 武警医学, 2014, 25（5）：529-532.
[27] Sonnichsen DS, Liu Q, Schuetz EG, et al. Variability in human cytochrome P450 paclitaxel metabolism[J]. J Pharmacol Exp Ther, 1995, 275（2）：566-575.
[28] Václavíková R, Horský S, Šimek P, et al. Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants[J]. Naunyn-Schmiedeberg’s Archives of Pharmacology, 2003, 368（3）：200-209.